Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
A wave of new biologic therapies is showing real promise for COPD patients who keep exacerbating despite standard inhaled treatments. From tezepelumab cutting hospital days by more than half, to tozorakimab slashing exacerbation rates by up to 34% across all patient types, to mixed but encouraging results with itepekimab and astegolimab — the era of targeted COPD biologics is arriving fast.
For the millions of COPD patients who still exacerbate despite maximal inhaled therapy, a new class of biologic treatments is delivering some of the most exciting clinical results in years. Data from multiple phase 2 and phase 3 trials — presented at the European Respiratory Society and American Thoracic Society conferences — show that add-on monoclonal antibodies can meaningfully reduce exacerbations, steroid use, and hospitalizations.
Tezepelumab (Tezspire) led to fewer hospital days (64 vs. 151) and fewer specialist visits in eosinophilic COPD patients over 52 weeks. Tozorakimab, targeting IL-33, cut moderate-to-severe exacerbations by 29–34% in the replicate phase 3 OBERON and TITANIA trials — crucially, across all blood eosinophil levels and smoking statuses, not just high-eosinophil patients. Itepekimab showed a significant 20–27% exacerbation reduction in one of two phase 3 trials (AERIFY-1), while astegolimab demonstrated a modest but significant ~15% reduction in a pooled phase 2b/3 analysis.
Why it matters: COPD remains one of the leading causes of death and disability worldwide, and existing biologics only work for a narrow eosinophilic subset. Tozorakimab's broad efficacy regardless of eosinophil count or smoking status could open targeted therapy to a much wider patient population — with an FDA decision expected in early 2027.
